Table 2 Substance use history and treatment characteristics of a sample receiving buprenorphine for opioid use disorder
From: Recovery capital among people receiving treatment for opioid use disorder with buprenorphine
Substance use history and treatment characteristics | Total | Men | Women | P value |
|---|---|---|---|---|
N (%) | N (%) | N (%) | ||
N = 130 | N = 59 | N = 71 | ||
Lifetime type of opioid use | 90 (69.2) | 49 (83.1) | 41 (57.7) | 0.005 |
 Heroin only | 14 (10.8) | 2 (3.4) | 12 (16.9) |  |
 Prescription opioid only | 26 (20.0) | 8 (13.6) | 18 (25.4) |  |
 Both | ||||
Lifetime most serious route of opioid use | Â | Â | Â | 0.04 |
 Injection | 63 (52.9) | 31 (57.4) | 32 (49.2) |  |
 Nasal | 45 (37.8) | 22 (40.7) | 23 (35.4) |  |
 Oral | 11 (9.2) | 1 (1.9) | 10 (15.4) |  |
Age onset opioid use | 24.36 ± 9.2 | 23.2 ± 8.5 | 25.36 ± 9.7 | 0.203 |
(Mean ± SD) |  |  |  |  |
Lifetime history overdose | 27 (35.1) | 17 (50.0) | 10 (23.3) | 0.015 |
Lifetime polysubstance use | 122 (93.8) | 57 (96.6) | 65 (91.5) | 0.232 |
# Lifetime treatment episodes [Median (IQR)] | 0.053 | |||
Daily opioid use at treatment entry (illicit or Rx misuse) | 98 (76.6) | 48 (82.8) | 50 (71.4) | 0.132 |
aLong-term MOUD with buprenorphine (≥ 1 year) | 74 (56.9) | 33 (55.9) | 41 (57.7) | 0.835 |
aLength of current treatment episode (days; Mean ± SD) | 396.1 ± 245.9 | 385.7 ± 239.3 | 404.8 ± 252.5 | 0.662 |